[Different treatment strategies in patients with HBeAg-positive and negative chronic hepatitis B].

Patients with HBeAg-positive and negative chronic hepatitis B (CHB) have different immunological states and disease progression. Hence, the previously recommended antiviral therapy strategies for the two are different. In recent years, the antiviral indications have gradually eased, and the treatment goal has began to pursue clinical cure, as experts and scholars have gradually attached importance to the potential risk of disease progression in hepatitis B patients. Antiviral treatment strategies are gradually becoming uniform for patients with HBeAg-positive and negative. However, among them, HBeAg-negative patients can be combined with HBsAg quantification and other indicators to further screen the clinically cured dominant population in order to formulate the next treatment strategy.HBeAg阳性和阴性慢性乙型肝炎（chronic hepatitis B，CHB）患者处于不同的免疫状态和疾病进程，既往推荐的抗病毒策略二者有所区别。近年来专家学者逐渐重视乙型肝炎患者疾病潜在进展风险，抗病毒指征逐渐放宽，治疗目标开始追求临床治愈。HBeAg阳性和阴性患者的抗病毒治疗策略渐趋一致。其中，HBeAg阴性患者可结合HBsAg定量等指标，进一步筛选临床治愈优势人群，以制定下一步治疗策略。.